A multicenter, retrospective, cohort study analysing efficacy of Ustekinumab for perianal active or inactive Crohn's Disease: The BioLAP Study From the GETAID
Latest Information Update: 31 Dec 2020
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms BioLAP study
- 31 Dec 2020 New trial record
- 01 Nov 2020 Results published in the American Journal of Gastroenterology